NRC of Canada

The National Research Council of Canada (NRC) is an agency of the Government of Canada, governed by a council of appointees drawn from its client community.

NRC is comprised of three integrated R&D divisions: emerging technologies; life sciences; and engineering. Each is guided by an advisory body comprising industry leaders. Under these three umbrella R&D divisions are 12 integrated and consolidated portfolios focused on key industry sectors, which represent areas of strategic importance and economic value for Canada.

NRC is partnering with KalGene Pharmaceuticals to co-develop a new treatment against aggressive brain cancers.


CIMTEC was created to facilitate and accelerate the commercialization of world-leading medical imaging technology. It provides a one-stop-shop of commercialization services to help researchers, start-ups and small to medium-sized companies translate their medical imaging innovations into commercial products for clinical use. By providing critically needed business expertise, technical capabilities and links to clinicians and infrastructure, CIMTEC helps its customers become internationally competitive. 

CIMTEC has a multi-year agreement with KalGene to provide extensive project management services, coordinating the expertise of world-leading research laboratories in multiple cities. In addition, its engineers are creating algorithms to quantify new biomarkers for the project.

Sunnybrook Research Institute

Sunnybrook Research Institute’s mandate is to make discoveries and achieve clinical impact. Its Biomarker Imaging Research Laboratory (BIRL), headed by Dr. Martin Yaffe, and the Angiogenic Signalling Laboratory (ASL), headed by Dr. Dan Dumont, are providing extensive expertise to the KalGene project. BIRL is working on optimizing immunohistochemistry (IHC) stains and developing multiplexed techniques, while ASL is testing a therapeutic that targets aggressive cancers, blocking the network and stopping metastatic spread, thereby improving patient survival.

Queen's logo

Queen’s University’s Ontario Cancer Biomarker Network (OCBN) has developed partnerships with national and international research teams. Its research focus includes a broad range of human diseases. In 2012, OCBN moved its proteomics "wet labs" to Queen's University where they were formally merged with the genomics labs located within the Department of Pathology and Molecular Medicine

For the KalGene project, OCBN is further contributing to the optimization of IHC staining, including clinical review.

MITACS   University of Toronto